Fennec Pharmaceuticals (FENC)

Fennec Pharmaceuticals (FENC) Income Statement


Fennec Pharmaceuticals Income Statement

Last quarter (Q4 2023), Fennec Pharmaceuticals's total revenue was $9.73M, an increase of 534.20% from the same quarter last year. In Q4, Fennec Pharmaceuticals's net income was $-2.68M. See Fennec Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 21.25M$ 21.25M$ 1.53M$ 0.00$ 170.00K$ 0.00
Cost of Revenue
$ 1.26M$ 1.26M$ 86.00K---
Gross Profit
$ 19.99M$ 19.99M$ 1.45M---
Operating Expense
$ 33.05M$ 33.05M$ 24.19M$ 17.22M$ 18.46M$ 13.07M
Operating Income
$ -13.06M$ -13.06M$ -22.74M$ -17.22M$ -18.29M$ -13.07M
Net Non Operating Interest Income Expense
$ -2.95M$ -2.95M$ -783.00K$ -88.00K$ -324.00K$ 315.00K
Other Income Expense
$ 39.00K$ 39.00K$ 184.00K$ -35.00K$ 100.00K$ -17.00K
Pretax Income
$ -16.05M$ -16.05M$ -23.71M$ -17.35M$ -18.11M$ -12.78M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -16.05M$ -16.05M$ -23.71M$ -17.35M$ -18.11M$ -12.78M
Basic EPS
$ -0.61$ -0.60$ -0.90$ -0.67$ -0.76$ -0.64
Diluted EPS
$ -0.61$ -0.60$ -0.90$ -0.67$ -0.76$ -0.64
Basic Average Shares
$ 106.30M$ 26.57M$ 26.27M$ 26.01M$ 23.70M$ 19.90M
Diluted Average Shares
$ 106.30M$ 26.57M$ 26.27M$ 26.01M$ 23.70M$ 19.90M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 26.71M$ 34.31M-$ 17.22M$ 18.46M$ 13.07M
Net Income From Continuing And Discontinued Operation
$ -16.05M$ -16.05M$ -23.71M$ -17.35M$ -18.11M$ -12.78M
Normalized Income
$ -11.79M$ -11.79M$ -17.43M$ -17.31M$ -18.21M$ -12.78M
Interest Expense
---$ 126.00K$ 9.00K-
$ -12.65M$ -12.65M$ -22.74M$ -17.22M$ -18.10M$ -13.07M
$ -12.36M$ -12.36M$ -22.59M$ -17.22M$ -18.10M$ -13.01M
Currency in USD

Fennec Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis